Type 2 diabetes is a progressive disease. As the years progress, more patients require different medicines and finally, injectable medicines. Some common medicines used in diabetes are further associated with weight gain and hypoglycemia. Diabetes therapies are evolving. Once a week therapies like Dulaglutide (marketed as Trulicity) have made it more convenient for patients.
Medicines in a class called “GLP-1receptor agonists “are associated with weight loss and no hypoglycemia, despite being very effective agents. We have been using medicines like Liraglutide (Victoza) for many years. The convenience has been enhanced by the Trulicity by making it a weekly therapy. The starting dose is 0.75 mg which can be increased to 1.5 mg/day. They have the capacity to reduce fasting blood sugars by 20-30 mg/dl and postprandial sugars by 40-50 mg/dl. HbA1c also came down by more than 1%. Unlike patients on insulin who gain weight, patients on Trulicity lose about 2-3 kg of weight. These drugs do not cause hypoglycemia (low sugars), however, some patients on Trulicity may experience some nausea and on rare occasions, vomiting. Most side effects disappear with continued use of these drugs. A new drug in this class called Lixisenatide (Lyxumia) is soon to hit the market.
Our diabetologists and endocrinologists are experienced in the use of GLP-1 receptor agonists including Victoza and Trulicity.